{"id":16103,"date":"2022-02-14T19:09:00","date_gmt":"2022-02-14T13:39:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=16103"},"modified":"2023-04-24T12:50:37","modified_gmt":"2023-04-24T07:20:37","slug":"treatment-resistant-depression-therapeutics-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market","title":{"rendered":"How to Cure Treatment-resistant Depression?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a039d1089319\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a039d1089319\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market\/#Treatment-resistant_Depression_Epidemiology\" >Treatment-resistant Depression Epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market\/#Treatment-resistant_Depression_Market\" >Treatment-resistant Depression Market<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market\/#Market_Leaders_in_the_Making\" >Market Leaders in the Making<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market\/#Treatment-resistant_Depression_Therapeutic_Trends\" >Treatment-resistant Depression Therapeutic Trends<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market\/#Treatment-resistant_Depression_Roadblocks\" >Treatment-resistant Depression Roadblocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market\/#Future_of_Treatment-resistant_Depression\" >Future of Treatment-resistant Depression<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Treatment-resistant Depression (TRD) typically refers to inadequate response to at least two antidepressant medications used for a sufficient length of time at an adequate dose with an adequate affirmation of treatment adherence. Treatment-resistant Depression is a relatively common occurrence in clinical practice, with 50\u201360% of the patients not achieving sufficient response following antidepressants for Treatment-resistant Depression.<\/p>\n\n\n\n<p>Treatment-resistant Depression is usually linked to higher rates of comorbidity, particularly with other psychiatric disorders, <a href=\"https:\/\/www.delveinsight.com\/blog\/chronic-pain-pipeline\">chronic pain<\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/fibromyalgia-market\">fibromyalgia<\/a>. On the other hand, the impact of both physical and psychiatric illness comorbidities is much higher amongst the patients. Some <a href=\"https:\/\/www.delveinsight.com\/blog\/mental-health-disease-causes-types-risk-factors-and-treatment-options\">environmental factors related to Treatment-resistant Depression<\/a> are lower socioeconomic status, non-supportive social environment, family conflicts, chronic stressors, multiple loss events, lower level of education, and social support and work dysfunction.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treatment-resistant-depression-epidemiology\"><span class=\"ez-toc-section\" id=\"Treatment-resistant_Depression_Epidemiology\"><\/span><strong>Treatment-resistant Depression Epidemiology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>To determine the prevalent population of Treatment-resistant Depression in the 7MM (United States, Germany, France, Spain, Italy, United Kingdom, and Japan), we considered and compared data from various studies and organizational databases. Along with this, we also collected different KOL views and expert opinions to cover the geographical differences in <a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-depression-epidemiology-forecast\">Treatment-resistant Depression epidemiology<\/a> across the 7MM.<\/p>\n\n\n\n<p>The total 7MM prevalent cases of Treatment-resistant Depression stood at nearly <strong>5.8 million <\/strong>in 2021. The United States accounted for the highest number of cases, followed by EU5 countries and Japan. Japan had ~<strong>270,000 cases<\/strong> of Treatment-resistant Depression in 2021, while the EU5 countries together accounted for over <strong>1.5 million cases<\/strong>, <strong>as per DelveInsight\u2019s assessments.<\/strong><\/p>\n\n\n\n<p>According to DelveInsight\u2019s estimates, among the European countries, <strong>Germany<\/strong> had the highest number of prevalent cases of Treatment-resistant Depression (~<strong>560k<\/strong>) in 2021 and is expected to reach <strong>~550k <\/strong>by 2032 owing to a declining population.<strong> <\/strong>At the same time, <strong>Italy<\/strong> had the lowest number of prevalent cases (<strong>~127k<\/strong>)<strong> <\/strong>in 2021, which as per DelveInsight\u2019s estimates, are expected to reach <strong>nearly 130k <\/strong>cases by 2032.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"481\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193911\/Treatment-resistant-depression-epidemiological-analysis-1024x481.png\" alt=\"\" class=\"wp-image-16127\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193911\/Treatment-resistant-depression-epidemiological-analysis-1024x481.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193911\/Treatment-resistant-depression-epidemiological-analysis-300x141.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193911\/Treatment-resistant-depression-epidemiological-analysis-150x71.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193911\/Treatment-resistant-depression-epidemiological-analysis-768x361.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193911\/Treatment-resistant-depression-epidemiological-analysis.png 1253w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">     <strong>Treatment-resistant Depression Epidemiology Analysis<\/strong>  <\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treatment-resistant-depression-market\"><span class=\"ez-toc-section\" id=\"Treatment-resistant_Depression_Market\"><\/span><strong>Treatment-resistant Depression Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to DelveInsight, the lion\u2019s share of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-depression-market\">Treatment-resistant Depression market <\/a>remains with the United States throughout the forecast period (2019\u20132032). The Treatment-resistant Depression market size in the US was ~<strong>USD 1,800 million<\/strong> in 2019 and is likely to reach ~<strong>USD 9,000 million<\/strong> by 2032.<\/p>\n\n\n\n<p>In 2019, among EU5, <strong>Germany <\/strong>accounted for the largest market size (<strong>USD<\/strong> <strong>150+ million<\/strong>), followed by the <strong>UK<\/strong> with ~<strong>USD 105 million<\/strong>,whereas <strong>Italy <\/strong>accounted for the smallest (~<strong>USD 35 million<\/strong>).<\/p>\n\n\n\n<p>The current therapeutic options <strong>Aripiprazole (Abilify), Brexpiprazole (Rexulti) <\/strong>or <strong>Quetiapine (Seroquel XR)<\/strong> are FDA-approved as add-on therapies to an antidepressant for Treatment-resistant Depression. The future of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-depression-market\">Treatment-resistant Depression market<\/a> looks promising with emerging therapies such as<strong> AXS-05 (Axsome Therapeutics), Cariprazine (AbbVie), Esketamine DPI (Celon Pharma), AV-101 (VistaGen Therapeutics), REL-1017 (Relmada Therapeutics, Inc. and Syneos Health ), <\/strong>and <strong>MIJ821 (Novartis Pharmaceuticals).<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"411\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193401\/treatment-resistant-depression-therapeutics-market-size-1024x411.png\" alt=\"treatment-resistant-depression-therapeutics-market-size\" class=\"wp-image-16123\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193401\/treatment-resistant-depression-therapeutics-market-size-1024x411.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193401\/treatment-resistant-depression-therapeutics-market-size-300x121.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193401\/treatment-resistant-depression-therapeutics-market-size-150x60.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193401\/treatment-resistant-depression-therapeutics-market-size-768x309.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193401\/treatment-resistant-depression-therapeutics-market-size-1536x617.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193401\/treatment-resistant-depression-therapeutics-market-size-2048x823.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193401\/treatment-resistant-depression-therapeutics-market-size-1568x630.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\"> <strong>Market Analysis of Treatment-resistant Depression<\/strong> <\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Market_Leaders_in_the_Making\"><\/span><strong>Market Leaders in the Making<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>With a cornucopia of drugs in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-depression-pipeline-insight\">Treatment-resistant Depression pipeline<\/a>, market size is projected to increase. Among the emerging therapies, the most promising ones include<strong> AXS-05 (Axsome Therapeutics) \u2013 a Phase II NMDA receptor antagonist with multimodal activity<\/strong>, <strong>Esketamine therapy \u2013 a Phase II NMDA antagonist<\/strong>, and <strong>REL-1017 \u2013 Phase III NMDAR Antagonist<\/strong>, among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treatment-resistant-depression-therapeutic-trends\"><span class=\"ez-toc-section\" id=\"Treatment-resistant_Depression_Therapeutic_Trends\"><\/span><strong>Treatment-resistant Depression Therapeutic Trends<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pharmacologic treatment options include <strong>switching, combination, and potentiation strategies among<\/strong> commonly used antidepressant drugs. Most of the available antidepressants, such as <strong>selective serotonin reuptake inhibitors (SSRIs), dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, irreversible, non-selective monoamine oxidase inhibitors (MAOIs), \u03b12-antagonists, agomelatine, <\/strong>and<strong> tianeptine<\/strong> are used to treat TRD.<\/p>\n\n\n\n<p>Non-pharmacological therapies include <strong>electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS).<\/strong> Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioural therapy (CBT) and interpersonal therapy (IPT).&nbsp;<\/p>\n\n\n\n<p>A relatively wide variety of treatment options for unipolar Treatment-resistant Depression are available, whilst the evidence is very scanty for bipolar TRD. Treatment-resistant Depression is associated with poor clinical, functional, and social outcomes. Several <a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-depression-pipeline-insight\">novel drug therapies that could tackle Treatment-Resistant Depression<\/a> are currently being investigated as promising alternatives, targeting the neurotransmitter system outside the standard monoamine hypothesis. Augmentation or combination with lithium or atypical antipsychotics appears as a valid option for both conditions, and the same occurs with electroconvulsive therapy. Other non-pharmacological strategies, such as deep brain stimulation for Treatment-resistant Depression may be promising alternatives for the future. Cognitive behaviour therapy is recommended for unipolar TRD, but there is no evidence supporting its use in <a href=\"https:\/\/www.delveinsight.com\/blog\/bipolar-depression-pipeline-therapies\">bipolar Treatment-resistant Depression<\/a>.<\/p>\n\n\n\n<p>Disease associations and other organized programs for Treatment-resistant Depression patients are established in most regions. Some prominent ones include the <strong>Vandrevala Foundation, Anxiety and Depression Association of America, Substance Abuse and Mental Health Services (SAMHSA), National Alliance on Mental Illness (NAMI), and Anxiety and Depression Association of America (ADAA)<\/strong>. These Treatment-resistant Depression support groups and organizations provide opportunities to map the patients and improve their access to innovative treatments and outcomes. Soon, establishing country-wide registries in cooperation with these centres may also help tackle the disease further.<\/p>\n\n\n\n<p>Before deciding that a patient is treatment-resistant, physicians should assess the adequacy of treatment by determining adherence to the Treatment-resistant Depression medication. Non-adherence is estimated to be between 20% and 50% of all patients. It is prevalent in persons with cognitive defects and feelings of worthlessness and hopelessness. Ongoing cognitive behaviour therapy (CBT) and frequent follow-up with the physician may encourage adherence during the early stages of treatment. In patients who have been determined adherent, obtaining serum drug levels may be helpful, especially in those taking tricyclic antidepressants. Particular attention should be paid to comorbid substance abuse or other psychiatric conditions because they can significantly complicate the <a href=\"https:\/\/www.delveinsight.com\/blog\/depression-signs-symptoms-risk-factors-types-and-treatment-options\">treatment of the underlying depression.<\/a><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"341\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193507\/treatment-resistant-depression-key-companies-1024x341.jpg\" alt=\"treatment-resistant-depression-key-companies\" class=\"wp-image-16124\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193507\/treatment-resistant-depression-key-companies-1024x341.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193507\/treatment-resistant-depression-key-companies-300x100.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193507\/treatment-resistant-depression-key-companies-150x50.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193507\/treatment-resistant-depression-key-companies-768x256.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193507\/treatment-resistant-depression-key-companies.jpg 1315w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">       <strong>Treatment-resistant Depression Market Players<\/strong> <\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treatment-resistant-depression-roadblocks\"><span class=\"ez-toc-section\" id=\"Treatment-resistant_Depression_Roadblocks\"><\/span><strong>Treatment-resistant Depression Roadblocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Patients with Treatment-resistant Depression may be affected by varying factors such as genetic, epigenetic, endocrine, and environmental factors, such as traumatic or stressful life events, which could collectively contribute to the heterogeneity of <a href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder\">Major Depressive Disorder<\/a> (MDD) or Treatment-resistant Depression. The exact biological pathophysiology behind MDD is unknown; the major focus of treatment until now has been targeting monoamine pathways. The monoamine theory recommends that depression results from a deficiency in one or more monoamines (serotonin, norepinephrine, and dopamine). However, monoamine pathways may be a factor of a much more intricate system of neural pathways that could form the basis of <a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\">Major Depressive Disorder<\/a> and resistance to treatment. Several pathways and biological procedures may have a role in the disease of MDD, including pathways that regulate serotonin, acetylcholine, dopamine, GABA, glutamate, opioid, norepinephrine, and vasoactive intestinal peptide, and have implications for patients with Treatment-resistant Depression.<\/p>\n\n\n\n<p>The treatment response of patients suffering from Treatment-resistant Depression varies from patient to patient. According to various researches, 10\u201330% of patients who take antidepressants for Treatment-resistant Depression experience a poor response with residual symptoms and are required to try a variety of treatment alternatives. As the disease course of TRD is variable, different patients may experience major depressive episodes (MDEs) of varying severity, frequency, and characteristics of symptomatic, which may affect treatment response. The clinically significant benefit of treatment depends on the initial severity of TRD, the degree of resistance to the antidepressant medication, and the rating scale used to assess benefits in symptom enhancements. Even with multiple antidepressant medications, patients with Treatment-resistant Depression do not always attain remission and often experience residual symptom burdens. Continued residual symptoms are associated with a higher risk of relapse, highlighting the urgent unmet need to manage for better long-term outcomes.<\/p>\n\n\n\n<p>Treatment-resistant Depression represents a chronic and complex illness that requires long-term management from medical specialists, which requires complete knowledge of adequate medication dose and duration. The retrospective studies from the health services database are frequently used to define the epidemiology and cost of Treatment-resistant Depression. The clinical information available in health services databases is quite limited and does not reflect the real-time clinical status of patients. Moreover, there is confusion in defining TRD, making it difficult to predict the exact prevalence and incidence rates across regions. Additionally, the discrepancy between diagnostic criteria and staging using different assessment scales is a source of confusion across multiple research settings. Hence, there is an urgent need to collect nationwide real-time data on this serious condition.<\/p>\n\n\n\n<p>Treatment-resistant Depression is widely <a href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder\">diagnosed as MDD<\/a> that does not respond or remit to one or more <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/anti-depressant\">antidepressant treatments<\/a> of adequate dose and duration. Nierenberg and Amsterdam introduced the term<strong> \u201cpseudo-resistance\u201d<\/strong> for indicating non-responsiveness in MDD patients due to reasons including the presence of inappropriate dose and duration of treatment, poor adherence by the patient, or important comorbidity that may affect response.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-of-treatment-resistant-depression\"><span class=\"ez-toc-section\" id=\"Future_of_Treatment-resistant_Depression\"><\/span><strong>Future of Treatment-resistant Depression<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As per DelveInsight\u2019s estimates, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-depression-market\">Treatment-resistant Depression market landscape<\/a> looks promising, studded with remarkable advances in diagnosis and treatments that will translate into a better quality of life and improved survival. The entry of the novel therapies to attain better healthcare will necessitate collaboration among academia, life-sciences companies, funding, regulatory agencies, decision-makers, and caregivers. In addition, expertise in navigating market access and reimbursement scenarios would be an elixir to devise successful GTM strategies for new therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-depression-trd-market\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193552\/treatment-resistant-depression-therapeutics-outlook-1024x256.png\" alt=\"treatment-resistant-depression-therapeutics-outlook\" class=\"wp-image-16125\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193552\/treatment-resistant-depression-therapeutics-outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193552\/treatment-resistant-depression-therapeutics-outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193552\/treatment-resistant-depression-therapeutics-outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193552\/treatment-resistant-depression-therapeutics-outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193552\/treatment-resistant-depression-therapeutics-outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193552\/treatment-resistant-depression-therapeutics-outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14193552\/treatment-resistant-depression-therapeutics-outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1644839862789\"><strong class=\"schema-faq-question\">What is Treatment-resistant Depression?<\/strong> <p class=\"schema-faq-answer\">Treatment-resistant Depression (TRD) refers to inadequate response to at least one antidepressant trial of adequate doses and duration.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1644839896097\"><strong class=\"schema-faq-question\">What causes Treatment-resistant Depression?<\/strong> <p class=\"schema-faq-answer\">Some medical conditions like heart disease, cancer, anorexia, or thyroid problems can contribute to Treatment-resistant Depression.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1644839920789\"><strong class=\"schema-faq-question\">What is the best antidepressant for Treatment-resistant Depression?<\/strong> <p class=\"schema-faq-answer\">Olanzapine-Fluoxetine (Symbyax) is a combination drug that contains the active ingredients in fluoxetine (Prozac) and olanzapine (Zyprexa) together in one tablet and is approved for Treatment-resistant Depression.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1644839936475\"><strong class=\"schema-faq-question\">What is FDA approved medication for Treatment-resistant Depression?<\/strong> <p class=\"schema-faq-answer\">Aripiprazole (Abilify), Brexpiprazole (Rexulti) or Quetiapine (Seroquel XR) are FDA-approved as add-on therapies to an antidepressant for Treatment-resistant Depression.<\/p> <\/div> <\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-\"><br><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><br><\/h3>\n","protected":false},"excerpt":{"rendered":"<p>Treatment-resistant-depression-epidemiological-analysis<\/p>\n","protected":false},"author":14,"featured_media":16115,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[2369,19095,19096,19088,19094,19089,19090],"industry":[17225],"therapeutic_areas":[17298],"class_list":["post-16103","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-depression","tag-trd","tag-trd-market","tag-treatment-resistant-depression","tag-treatment-resistant-depression-epidemiology","tag-treatment-resistant-depression-market","tag-treatment-resistant-depression-pipeline","industry-pharmaceutical","therapeutic_areas-mental-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Treatment-resistant Depression is on the Rise. Explore TRD Therapeutics<\/title>\n<meta name=\"description\" content=\"Treatment-resistant Depression Market looks promising with advances in diagnosis &amp; treatment that will translate into better quality of life\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Treatment-resistant Depression is on the Rise. Explore TRD Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Treatment-resistant Depression Market looks promising with advances in diagnosis &amp; treatment that will translate into better quality of life\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-14T13:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-24T07:20:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14192346\/treatment-resistant-depression-therapeutics-market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Treatment-resistant Depression is on the Rise. Explore TRD Therapeutics","description":"Treatment-resistant Depression Market looks promising with advances in diagnosis & treatment that will translate into better quality of life","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market","og_locale":"en_US","og_type":"article","og_title":"Treatment-resistant Depression is on the Rise. Explore TRD Therapeutics","og_description":"Treatment-resistant Depression Market looks promising with advances in diagnosis & treatment that will translate into better quality of life","og_url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-02-14T13:39:00+00:00","article_modified_time":"2023-04-24T07:20:37+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14192346\/treatment-resistant-depression-therapeutics-market.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market","url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market","name":"Treatment-resistant Depression is on the Rise. Explore TRD Therapeutics","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14192346\/treatment-resistant-depression-therapeutics-market.png","datePublished":"2022-02-14T13:39:00+00:00","dateModified":"2023-04-24T07:20:37+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Treatment-resistant Depression Market looks promising with advances in diagnosis & treatment that will translate into better quality of life","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839862789"},{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839896097"},{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839920789"},{"@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839936475"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14192346\/treatment-resistant-depression-therapeutics-market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14192346\/treatment-resistant-depression-therapeutics-market.png","width":772,"height":482,"caption":"treatment-resistant-depression-therapeutics-market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839862789","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839862789","name":"What is Treatment-resistant Depression?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Treatment-resistant Depression (TRD) refers to inadequate response to at least one antidepressant trial of adequate doses and duration.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839896097","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839896097","name":"What causes Treatment-resistant Depression?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Some medical conditions like heart disease, cancer, anorexia, or thyroid problems can contribute to Treatment-resistant Depression.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839920789","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839920789","name":"What is the best antidepressant for Treatment-resistant Depression?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Olanzapine-Fluoxetine (Symbyax) is a combination drug that contains the active ingredients in fluoxetine (Prozac) and olanzapine (Zyprexa) together in one tablet and is approved for Treatment-resistant Depression.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839936475","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/treatment-resistant-depression-therapeutics-market#faq-question-1644839936475","name":"What is FDA approved medication for Treatment-resistant Depression?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Aripiprazole (Abilify), Brexpiprazole (Rexulti) or Quetiapine (Seroquel XR) are FDA-approved as add-on therapies to an antidepressant for Treatment-resistant Depression.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/14192346\/treatment-resistant-depression-therapeutics-market-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">depression<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TRD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TRD Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Treatment-resistant Depression<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Treatment-resistant Depression epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Treatment-resistant Depression market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Treatment-resistant Depression pipeline<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">depression<\/span>","<span class=\"advgb-post-tax-term\">TRD<\/span>","<span class=\"advgb-post-tax-term\">TRD Market<\/span>","<span class=\"advgb-post-tax-term\">Treatment-resistant Depression<\/span>","<span class=\"advgb-post-tax-term\">Treatment-resistant Depression epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Treatment-resistant Depression market<\/span>","<span class=\"advgb-post-tax-term\">Treatment-resistant Depression pipeline<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Feb 14, 2022","modified":"Updated on Apr 24, 2023"},"absolute_dates_time":{"created":"Posted on Feb 14, 2022 7:09 pm","modified":"Updated on Apr 24, 2023 12:50 pm"},"featured_img_caption":"treatment-resistant-depression-therapeutics-market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=16103"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16103\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/16115"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=16103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=16103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=16103"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=16103"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=16103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}